Klin Monbl Augenheilkd 2013; 230(12): 1225-1229
DOI: 10.1055/s-0032-1328695
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Charles-Bonnet-Syndrom – klinische Besonderheiten eines faszinierenden Krankheitsbilds

Charles Bonnetʼs Syndrome: Clinical Insights in a Fascinating Disease
H. M. Elflein
Augenklinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg Universität Mainz
› Author Affiliations
Further Information

Publication History

eingereicht 26 April 2013

akzeptiert 07 May 2013

Publication Date:
06 September 2013 (online)

Zusammenfassung

Auch psychisch gesunde, kognitiv völlig unauffällige Personen können visuelle Halluzinationen wahrnehmen, die als Charles-Bonnet-Syndrom (CBS) bezeichnet werden – benannt nach einem Schweizer Wissenschaftler, der solche Wahrnehmungen erstmals im 18. Jahrhundert beschrieben hat. Den Betroffenen ist der nichtreale Charakter der Halluzinationen in der Regel bewusst. Die Definitionen des CBS sind nicht einheitlich. So ist etwa eine Sehbehinderung oder Blindheit nicht in allen Definitionen gefordert, dieses Kriterium ist dennoch häufig assoziiert mit dem CBS. Weil die Prävalenz gerade bei Sehbehinderten oder Blinden hoch ist, sollten Augenärzte dieses Syndrom kennen: betroffene Patienten berichten aus Angst vor Stigmatisierung häufig nicht von sich aus von ihren Wahrnehmungen. Möglicherweise sind Frauen häufiger betroffen als Männer. Das CBS ist vor allem bei älteren Menschen gut untersucht, aber auch junge Menschen können visuelle Halluzinationen wahrnehmen. Inhalt der Wahrnehmungen sind häufig Personen, die Wahrnehmungen können unterschiedlich lang andauern. Die meisten Patienten erleben mehrere Episoden von visuellen Wahrnehmungen. Am besten untersucht ist das CBS bei Patienten mit Sehbehinderung aufgrund einer AMD. Neuroradiologische Untersuchungen haben gezeigt, dass auch zerebrale Veränderungen, vor allem im Bereich des okzipitalen Kortex, eine Rolle spielen in der Entstehung visueller Wahrnehmungen. Vielen Patienten ist allein schon durch ein aufklärendes Gespräch geholfen, eine (medikamentöse) Therapie ist in der Regel nicht erforderlich. Die zugrunde liegende Pathophysiologie ist nicht geklärt, es gibt jedoch Erklärungsmodelle.

Abstract

Even mentally and cognitively healthy people can experience visual hallucinations. These are called Charles Bonnetʼs syndrome, named after the Swiss scientist, who first described such perceptions in the 18th century. Usually patients possess insight in the unreality of their visual experiences. The definitions of CBS are not consistent. Visual impairment or blindness is not part of every definition, but often is associated with CBS. Ophthalmologists should be aware of this syndrome, since its prevalence is high among blind or visually impaired people: patients often are reluctant to admit their hallucinatory experiences, because of the fear of being stigmatised. Possibly women are affected more often than men. CBS is well investigated in the elderly, but also young people might experience visual hallucinations. Hallucinatory contents commonly are persons, with varying duration of the hallucinations. Most patients experience more than one hallucinatory episode. CBS is best investigated in patients suffering from AMD. Neuroimaging studies suggest that cerebral abnormalities, mainly in the occipital cortex, might also play a role in the pathogenesis of CBS. Many patients do not require (drug) treatment, since education itself is helpful in most cases. The pathophysiology remains unclear, but there are a couple of theories.

 
  • Referenzen

  • 1 Hedges jr. TR. Charles Bonnet, his life, and his syndrome. Surv Ophthalmol 2007; 52: 111-114
  • 2 de Morsier G. [The Charles Bonnet syndrome: visual hallucinations in the aged without mental deficiency]. Ann Med Psychol (Paris) 1967; 2: 678-702
  • 3 Menon GJ, Rahman I, Menon SJ et al. Complex visual hallucinations in the visually impaired: the Charles Bonnet Syndrome. Surv Ophthalmol 2003; 48: 58-72
  • 4 El-Mallakh RS, Walker KL. Hallucinations, psuedohallucinations, and parahallucinations. Psychiatry 2010; 73: 34-42
  • 5 Liester MB. Toward a new definition of hallucination. Am J Orthopsychiatry 1998; 68: 305-312
  • 6 Schadlu AP, Schadlu R, Shepherd 3rd JB. Charles Bonnet syndrome: a review. Curr Opin Ophthalmol 2009; 20: 219-222
  • 7 Gold K, Rabins PV. Isolated visual hallucinations and the Charles Bonnet syndrome: a review of the literature and presentation of six cases. Compr Psychiatry 1989; 30: 90-98
  • 8 Ffytche DH. Visual hallucinatory syndromes: past, present, and future. Dialogues Clin Neurosci 2007; 9: 173-189
  • 9 Merabet LB, Maguire D, Warde A et al. Visual hallucinations during prolonged blindfolding in sighted subjects. J Neuroophthalmol 2004; 24: 109-113
  • 10 Shiraishi Y, Terao T, Ibi K et al. The rarity of Charles Bonnet syndrome. J Psychiatr Res 2004; 38: 207-213
  • 11 Abbott EJ, Connor GB, Artes PH et al. Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome). Invest Ophthalmol Vis Sci 2007; 48: 1416-1423
  • 12 Vukicevic M, Fitzmaurice K. Butterflies and black lacy patterns: the prevalence and characteristics of Charles Bonnet hallucinations in an Australian population. Clin Experiment Ophthalmol 2008; 36: 659-665
  • 13 Singh A, Sorensen TL. The prevalence and clinical characteristics of Charles Bonnet Syndrome in Danish patients with neovascular age-related macular degeneration. Acta Ophthalmol 2012; 90: 476-480
  • 14 Teunisse RJ, Cruysberg JR, Verbeek A et al. The Charles Bonnet syndrome: a large prospective study in The Netherlands. A study of the prevalence of the Charles Bonnet syndrome and associated factors in 500 patients attending the University Department of Ophthalmology at Nijmegen. Br J Psychiatry 1995; 166: 254-257
  • 15 Tan CS, Lim VS, Ho DY et al. Charles Bonnet syndrome in Asian patients in a tertiary ophthalmic centre. Br J Ophthalmol 2004; 88: 1325-1329
  • 16 Singh A, Sorensen TL. Charles Bonnet syndrome improves when treatment is effective in age-related macular degeneration. Br J Ophthalmol 2011; 95: 291-292
  • 17 Khan JC, Shahid H, Thurlby DA et al. Charles Bonnet syndrome in age-related macular degeneration: the nature and frequency of images in subjects with end-stage disease. Ophthalmic Epidemiol 2008; 15: 202-208
  • 18 Teunisse RJ, Cruysberg JR, Hoefnagels WH et al. Visual hallucinations in psychologically normal people: Charles Bonnetʼs syndrome. Lancet 1996; 347: 794-797
  • 19 Yacoub R, Ferrucci S. Charles Bonnet syndrome. Optometry 2011; 82: 421-427
  • 20 Jackson ML, Bassett K, Nirmalan PV et al. Contrast sensitivity and visual hallucinations in patients referred to a low vision rehabilitation clinic. Br J Ophthalmol 2007; 91: 296-298
  • 21 Holroyd S, Rabins PV. A three-year follow-up study of visual hallucinations in patients with macular degeneration. J Nerv Ment Dis 1996; 184: 188-189
  • 22 Cebulla CM, Minning C, Pratt C et al. Charles Bonnet syndrome and Tersonʼs syndrome from subarachnoid hemorrhage: good news from bad news. Graefes Arch Clin Exp Ophthalmol 2012; DOI: 10.1007/s00417-012-2234-y.
  • 23 Ffytche DH, Howard RJ, Brammer MJ et al. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci 1998; 1: 738-742
  • 24 Adachi N, Watanabe T, Matsuda H et al. Hyperperfusion in the lateral temporal cortex, the striatum and the thalamus during complex visual hallucinations: single photon emission computed tomography findings in patients with Charles Bonnet syndrome. Psychiatry Clin Neurosci 2000; 54: 157-162
  • 25 Sichart U, Fuchs T. [Visual hallucinations in elderly patients with reduced vision: Charles Bonnet syndrome]. Klin Monatsbl Augenheilkd 1992; 200: 224-227
  • 26 Kishi T, Uegaki J, Kitani M et al. The usefulness of single photon emission computed tomography in Charles Bonnet syndrome: a case with occipital lobe involvement. Gen Hosp Psychiatry 2000; 22: 132-135
  • 27 Kazui H, Ishii R, Yoshida T et al. Neuroimaging studies in patients with Charles Bonnet Syndrome. Psychogeriatrics 2009; 9: 77-84
  • 28 Billings FT, Pitt J. Charles Bonnet low visions. Trans Am Clin Climatol Assoc 2008; 119: 225-226
  • 29 Crumbliss KE, Taussig MJ, Jay WM. Vision rehabilitation and Charles Bonnet Syndrome. Semin Ophthalmol 2008; 23: 121-126
  • 30 Segers K. Charles Bonnet syndrome disappearing with carbamazepine and valproic acid but not with levetiracetam. Acta Neurol Belg 2009; 109: 42-43
  • 31 McKoy JM, McGartland L. Visual hallucinations in an elderly woman: a presentation of Charles Bonnet syndrome?. J Am Geriatr Soc 2006; 54: 723-725
  • 32 Coletti Moja M, Milano E, Gasverde S et al. Olanzapine therapy in hallucinatory visions related to Bonnet syndrome. Neurol Sci 2005; 26: 168-170
  • 33 Lerario A, Ciammola A, Poletti B et al. Charles Bonnet syndrome: two case reports and review of the literature. J Neurol 2013; 260: 1180-1186
  • 34 Garcia-Ptacek S, Garcia Azorin D, Sanchez Salmador R et al. Hallucinations and aberrant perceptions are prevalent among the young healthy adult population. Neurologia 2013; 28: 19-23
  • 35 Levine AM. Visual hallucinations and cataracts. Ophthalmic Surg 1980; 11: 95-98
  • 36 Cogan DG. Visual hallucinations as release phenomena. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1973; 188: 139-150
  • 37 Asaad G, Shapiro B. Hallucinations: theoretical and clinical overview. Am J Psychiatry 1986; 143: 1088-1097
  • 38 Berrios GE, Brook P. The Charles Bonnet syndrome and the problem of visual perceptual disorders in the elderly. Age Ageing 1982; 11: 17-23
  • 39 Schultz G, Melzack R. The Charles Bonnet syndrome: ʼphantom visual imagesʼ. Perception 1991; 20: 809-825